Document is current
Any future updates will be listed below
-
Authors
Maurer, Katie https://orcid.org/0000-0002-4160-181X
Weir, Jackson A. https://orcid.org/0000-0001-8741-1344
Nagler, Adi
Haradhvala, Nicholas J. https://orcid.org/0000-0003-1113-3135
Bharadwaj, Hariharan https://orcid.org/0000-0003-4550-4811
Shapiro, Jacob
Alakwe, Somkene
Kumar, Vipin
Waller, Brianna
McDonough, Mikaela
Dela Cruz, Jamie
Luna, Loida
Lin, Emma
Gong, Linsey
Gong, Qiyu
Borji, Mehdi
Michaels, Phillip D.
Laubach, Jacob P.
Pinkus, Geraldine
Getz, Gad https://orcid.org/0000-0002-0936-0753
Wu, Catherine J.
Chen, Fei https://orcid.org/0000-0003-2308-3649
Jacobson, Caron
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA276865)
- License Information
-
More Information
Article History
Received: 2 February 2025
Accepted: 21 July 2025
First Online: 12 August 2025
Competing interests
: C.J. reports consultancy for Kite/Gilead, BMS/Celgene, Novartis, Instil Bio, ImmPACT Bio, Caribou Bio, Miltenyi, Ipsen, ADC Therapeutics, Abbvie, AstraZeneca, Morphosys, Synthekine, and Sana, and research funding from Kite/Gilead and Pfizer. C.J.W. is an equity holder of BioNTech, Inc., receives research funding from Pharmacyclics, and is on the SAB of Repertoire, Adventris, Nature’s Toolbox, Aethon Therapeutics. F.C. is an academic founder of Curio Bioscience and Doppler Biosciences, and a scientific advisor for Amber Bio. F.C.'s interests were reviewed and managed by the Broad Institute in accordance with their conflict-of-interest policies. The remaining authors declare no competing interests.
